- The FDA approves the use of Celgene's (NASDAQ:CELG) REVLIMID (lenalidomide) for the treatment of patients with multiple myeloma (MM) as maintenance therapy following autologous hematopoietic stem cell transplant, the first such approval in the U.S. for the indication.
- The FDA approved REVLIMID, in combination with dexamethasone, in June 2006 for the treatment of patients with MM who have received at least one prior line of therapy. In February 2015, the label was expanded to include patients with newly diagnosed MM.